Novartis (NVS)
(Delayed Data from NYSE)
$120.89 USD
+0.47 (0.39%)
Updated Aug 30, 2024 04:00 PM ET
After-Market: $120.83 -0.06 (-0.05%) 7:58 PM ET
3-Hold of 5 3
B Value D Growth C Momentum C VGM
Novartis (NVS) Price Targets
Average Price Target | Highest Price Target | Lowest Price Target | Upside to Average Price Target |
---|---|---|---|
$122.08 | $135.00 | $114.00 | 0.98% |
Price Target
Based on short-term price targets offered by six analysts, the average price target for Novartis comes to $122.08. The forecasts range from a low of $114.00 to a high of $135.00. The average price target represents an increase of 0.98% from the last closing price of $120.89.
Analyst Price Targets (6 )
Broker Rating
Novartis currently has an average brokerage recommendation (ABR) of 2.57 on a scale of 1 to 5 (Strong Buy to Strong Sell), calculated based on the actual recommendations (Buy, Hold, Sell etc.) made by 14 brokerage firms. The current ABR compares to an ABR of 2.57 a month ago based on 14 recommendations.
Of the 14 recommendations deriving the current ABR, four are Strong Buy, representing 28.57% of all recommendations. A month ago, Strong Buy represented 28.57%.
Broker Rating Breakdown
![Broker Rating Visualization](https://widget3.zacks.com/images/charts/bar/brokerage/bar/NVS.png)
Brokerage Recommendations
Today | 1 Week Ago | 1 Month Ago | 2 Months Ago | 3 Months Ago | |
---|---|---|---|---|---|
Strong Buy | 4 | 4 | 4 | 4 | 4 |
Buy | 0 | 0 | 0 | 0 | 0 |
Hold | 9 | 9 | 9 | 8 | 8 |
Sell | 0 | 0 | 0 | 0 | 0 |
Strong Sell | 1 | 1 | 1 | 1 | 0 |
ABR | 2.57 | 2.57 | 2.57 | 2.54 | 2.33 |
1. Not Ident. Many of the brokerage firms who provide Zacks data ask that we keep their identity confidential.
2. In most cases the # of brokers listed above is less than the # of brokerage firms that have a recommendation on the stock. That is because some firms prohibit Zacks from displaying detailed information on their recommendations such as in the upgrade/downgrade table.
Analyst Upgrades/Downgrades
Date | Brokerage Firm | Analyst | Previous | Current |
---|---|---|---|---|
7/2/2024 | Berenberg Bank | Kerry Holford | Hold | Hold |
6/24/2024 | Not Identified | Not Identified | Not Available | Strong Sell |
5/30/2024 | Goldman Sachs | James Quigley | Not Available | Strong Buy |
4/26/2024 | Not Identified | Not Identified | Strong Buy | Strong Buy |
4/24/2024 | BMO Capital Markets | Etzer Darout | Hold | Hold |
4/23/2024 | Not Identified | Not Identified | Hold | Hold |
4/1/2024 | Cowen & Co. | Steve M Scala | Hold | Hold |
1/31/2024 | Not Identified | Not Identified | Strong Buy | Strong Buy |
1/2/2024 | Not Identified | Not Identified | Hold | Hold |
12/18/2023 | Not Identified | Not Identified | Strong Buy | Hold |
1. Not Ident. Many of the brokerage firms who provide Zacks data ask that we keep their identity confidential.
2. In most cases the # of brokers listed above is less than the # of brokerage firms that have a recommendation on the stock. That is because some firms prohibit Zacks from displaying detailed information on their recommendations such as in the upgrade/downgrade table.
Average Brokerage Rating
Current ABR | 2.57 |
ABR (Last week) | 2.57 |
# of Recs in ABR | 14 |
Average Target Price | $122.08 |
LT Growth Rate | 9.20% |
Industry | Large Cap Pharmaceuticals |
Industry Rank by ABR | 84 of 253 |
Current Quarter EPS Est: | 1.91 |